Clinical Trials Logo

Refractory Thoracic Tumors clinical trials

View clinical trials related to Refractory Thoracic Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03583086 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Start date: July 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who have progressed on platinum-based chemotherapy, and thymic carcinoma.